Siemens Healthineers logo; HeartFlow logo
Siemens Healthineers and HeartFlow® Collaborate to Provide Solution
That Has Potential to Lower Cardiac Care Costs
Global agreement allows companies to develop integrated, noninvasive
care solutions for improved management of coronary artery disease
patients; the collaboration’s joint solution pairs CT scanners from
Siemens Healthineers with the HeartFlow FFRct Analysis
ERLANGEN, Germany and REDWOOD CITY, Calif. USA - March 16, 2017
- Siemens Healthineers and HeartFlow, Inc. have entered into a global
collaboration agreement to provide a comprehensive, noninvasive solution to
support the diagnosis and management of patients with suspected coronary
artery disease (CAD). HeartFlow is a pioneer in personalized medical
technology to aid in the diagnosis and treatment of CAD. Siemens
Healthineers aims to enable healthcare providers to meet current challenges
and excel in their respective environments. To execute this strategy in the
field of cardiology, Siemens Healthineers is collaborating with HeartFlow and
contributing its strength in computed tomography (CT).
The collaboration’s joint solution pairs CT scanners from Siemens
Healthineers, which provide excellent image quality, with the HeartFlow
FFRct Analysis, the first noninvasive technology to provide insight into both
the extent of coronary artery disease and the impact that disease has on
blood flow to the heart.
Using CT images, the HeartFlow FFRct Analysis creates a personalized 3D
model of each patient’s arteries; computer algorithms then simulate blood
flow and assess the impact of arterial blockages. The combined clinical
pathway of coronary CT angiography (cCTA) and the HeartFlow FFRct
Analysis offers actionable information that helps physicians determine each
patient’s optimal course of treatment. Published clinical data1 demonstrate
that use of the HeartFlow FFRct Analysis may prevent unnecessary invasive
Although the United States is the initial commercial focus of this collaboration
agreement, the two companies plan to expand their efforts to additional
geographic markets in the future.
“It is a fact that the treatment planning for coronary artery disease patients
can be improved via quantitative data out of FFR measurements. With our
exciting partnership between Siemens Healthineers and HeartFlow, Inc., we
create an integrated solution that combines the exceptional cCTA images
acquired by our high performance scanners with the only commercial product
available that can derive FFR analysis noninvasively from CT data,” said
André Hartung, Head of Computed Tomography at Siemens Healthineers.
“HeartFlow is pleased to collaborate with Siemens Healthineers, with its
outstanding technology, tremendous expertise, and global reach,” said John
H. Stevens, MD, chairman and CEO of HeartFlow. “Like HeartFlow, Siemens
Healthineers is deeply committed to helping clinicians improve the patient
experience and clinical outcomes while also helping them to reduce the total
cost of healthcare. By working together, we can ensure this technology gets
to every patient who can benefit from it.”
About Siemens Healthineers
Siemens Healthineers is the separately managed healthcare business of
Siemens AG enabling healthcare providers worldwide to meet their current
challenges and to excel in their respective environments. A leader in medical
technology, Siemens Healthineers is constantly innovating its portfolio of
products and services in its core areas of diagnostic and therapeutic imaging
and in laboratory diagnostics and molecular medicine. Siemens Healthineers
is also actively developing its digital health services and enterprise services.
To help customers succeed in today’s dynamic healthcare marketplace,
Siemens Healthineers is championing new business models that maximize
opportunity and minimize risk for healthcare providers.
In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers
generated revenue of €13.5 billion and net income of over €2.3 billion and
has about 46,000 employees worldwide. Further information is available at
About HeartFlow, Inc.
HeartFlow, Inc. is a personalized medical technology company seeking to
transform the way cardiovascular disease is diagnosed and treated. The
company’s HeartFlow FFRct Analysis is the first available non-invasive
solution that enables a physician to more accurately evaluate whether a
patient has significant coronary artery disease (CAD) based on both anatomy
and physiology. The solution, which leverages deep learning to create a
personalized 3D model of the patient’s arteries, is well positioned to become
an integral part of the standard of care for patients who are at risk for CAD
because of its potential to improve clinical outcomes, improve the patient
experience and reduce the cost of care. The HeartFlow FFRct Analysis is
available in the United States, Canada, Europe and Japan. For more
information visit
1 Douglas, P.S., DeBruyne, B., Pontone, G., Patel, MR, et al. (2016). 1-Year
Outcomes of FFRCT-Guided Care in Patients with Suspected Coronary
Disease: The PLATFORM Study. J Am Coll Cardiol, 68(5), 435-45.
Siemens Healthineers
Ulrich Kuenzel,
+49 9131 84-3473
HeartFlow, Inc.
Chris B. Ernst
+1 415 710-9445
# # #
CCM-100-127 B